Zinzino AB (publ): Interim Report Second Quarter 2021
Increased Profit Forecast After Another Strong Quarter
STOCKHOLM, Aug. 27, 2021 /PRNewswire/ -- The second quarter of 2021 was yet another quarter in which good sales growth was combined with high profitability. Total revenues in the Group increased by 18% and amounted to SEK 322.4 (274.3) million. EBITDA result amounted to SEK 33.4 (16.0) million for the quarter and the EBITDA margin amounted to 10.4% (5.8%). The margin improvement is achieved through economies of scale due to improved efficiency in IT systems, logistics and within the organization. During the quarter, sales started in India, and Malaysia achieved full market status. In addition, the new products BalanceOil+ Premium and ZinzinoGene+ were launched.
The good profitability during the first half of the year means that the board writes up the profit forecast for the full year. The expected EBITDA margin for the full year is now adjusted up from at least 6% to between 8% -11%. The total income for the full year is expected to exceed SEK 1,400 million.
APRIL-JUNE
Total revenues increased by 18% to SEK 322.4 (274.3) million
Gross profit amounted to SEK 105.1 (73.5) million and the gross profit margin was 32.6% (26.8%)
EBITDA amounted to SEK 33.4 (16.0) million and the EBITDA margin to 10.4% (5.8%)
Cash flow from operating activities amounted to SEK 22.4 (19.9) million
The Board adjusts the expected EBITDA margin for the full year to 8% -11%
JANUARY-JUNE
Total revenues increased by 27% to SEK 655.8 (516.4) million
Gross profit was SEK 206.3 (157.2*) million and the gross profit margin was 31.5% (30.4%*)
Adjusted gross profit was SEK 206.3 (135.0*) million and the adjusted gross profit margin was 31.5% (26.1%*)
EBITDA was SEK 70.7 (42.3*) million and the EBITDA margin was 10.8% (8.2%*)
Adjusted EBITDA was SEK 70.7 (20.1*) million and the adjusted EBITDA margin was 10.8% (3.9%*)
Cash flow from operating activities was SEK 70.4 (52.5) million
Cash and cash equivalents at the balance sheet date amounted to SEK 166.9 (107.2) million
* For comparative figures for the first half of 2020 gross profit and EBITDA are affected with SEK 22.2 million due to a change in accounting as a result of changes in distributor remuneration terms
For more information:
Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, zinzino.com
Erik Penser Bank Aktiebolag, +46 (0) 8 463 83 00, email: [email protected]
Zinzino AB (publ) is obliged to publish this information in compliance with current EU regulations governing market abuse. The information was provided by the above contact person for publication at 08.00 the 27th of August 2021.
Arthrex, a global leader in minimally invasive surgical technology, has once again taken home prestigious medals for product innovation at the 37th annual Edison Awards.
"This product, along with our other innovations,...
Aligned with the trend of immersive water therapy in 2024, Baros Maldives' Serenity Spa stands out as an oasis of indulgent spa and beauty rituals, boasting a 50-year legacy of luxury. Nestled within a tranquil sanctuary amidst the lush Maldivian...
Oragenics, Inc. , a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it received a notice (the "Notice") from the NYSE American LLC (the "NYSE American") dated April...
Building on a successful phase one in which STChealth proved that the Universal Patient Identifier (UPI)?powered by Experian Health's Universal Identity Manager (UIM) and NCPDP Standardstm?can accurately identify patients across multiple datasets in...
StateHouse Holdings Inc. ("StateHouse" or the "Company") , a California-focused, vertically integrated cannabis company, today announced further to its press release dated April 15, 2024, that the Ontario Securities Commission (the "OSC") has denied...
Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announces the filing of its Annual Report on Form 20-F for the fiscal year ended December 31,...